Select Page

South Delhi Pharma, New Delhi, India

POLIVY ™ (polatuzumab vedotin-piiq) for injection

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

POLIVY is a prescription medicine. POLIVY is used to treat iffuse large B-cell lymphoma.
INDICATIONS AND USAGE
POLIVY is a CD79b-directed antibody–drug conjugate indicated in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies.
Accelerated approval was granted for this indication based on complete response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory
trial.
DOSAGE FORMS & STRENGTHS
For injection: 140 mg of polatuzumab vedotin-piiq as a lyophilized powder in a single-dose vial.
Manufactured By: Genentech
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “POLIVY ™ (polatuzumab vedotin-piiq) for injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

14 + 4 =

Polatuzumab vedotin (INN; brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab. The drug was developed by Genentech and Roche.

5 reviews for POLIVY ™ (polatuzumab vedotin-piiq) for injection

  1. Earn Online

    I just could not leave your site prior to suggesting that I really enjoyed the usual info a person supply in your visitors? Is gonna be back regularly to check out new posts.

    https://www.blogexpander.com/just-starting-out-with-article-advertising-heres-what-you-need-to-know/

  2. zortilonrel

    I gotta favorite this website it seems invaluable very helpful

    http://www.zortilonrel.com/

  3. Dr. Gőz Péter ügyvéd Debrecen

    Greetings from California! I’m bored to death at work so I decided to check out your site on my iphone during lunch break. I enjoy the knowledge you provide here and can’t wait to take a look when I get home. I’m amazed at how quick your blog loaded on my phone .. I’m not even using WIFI, just 3G .. Anyways, awesome site!

    https://g.page/dr-goz-peter-ugyved-debrecen

  4. read

    This design is incredible! You certainly know how to keep a reader entertained. Between your wit and your videos, I was almost moved to start my own blog (well, almost…HaHa!) Great job. I really enjoyed what you had to say, and more than that, how you presented it. Too cool!

    http://caksandi.com/2021/07/02/an-incredibly-interesting-website-along-with-excellent-articles/

  5. bluebird.com

    What i do not realize is actually how you’re not actually much more well-liked than you might be now. You are very intelligent. You realize thus significantly relating to this subject, produced me personally consider it from a lot of varied angles. Its like men and women aren’t fascinated unless its one thing to accomplish with Lady gaga! Your own stuffs nice. Always maintain it up!

    https://rso.mui.ac.ir/searching-auto-article-are-some-guidelines-info-num-44-509

Add a review

Your email address will not be published.